# A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

> **NCT07313891** · PHASE3 · WITHDRAWN · sponsor: **Relmada Therapeutics, Inc.**

## Conditions studied

- Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
- Bladder (Urothelial, Transitional Cell) Cancer
- Urothelial Carcinoma Bladder
- Urologic Cancer

## Interventions

- **DRUG:** NDV-01 (sustained-release gemcitabine-docetaxel)

## Key facts

- **NCT ID:** NCT07313891
- **Lead sponsor:** Relmada Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-05-01
- **Primary completion:** 2029-09-01
- **Final completion:** 2029-11-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study has been incorporated into the Relmada REL-NDV01-303 study.
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07313891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07313891, "A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07313891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*